Advancing MOGAD Care

No Label: Michael Levy, MD, PhD No Label: Peter V. Sguigna, MD What do the latest METEOROID trial results mean for neurologists treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)? Michael Levy, MD, Massachusetts General Hospital, Boston, MA, discusses relapse prevention, diagnostic challenges, and the future of MOGAD management with Peter Sguigna, MD, UT Southwestern Medical Center, Dallas, TX.

Episode metadata supplied by the publisher feed · Published Jun 24, 2026

Embed this episode

Attribution link and audio player

Ready to play

Advancing MOGAD Care

0:00 10:04

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

Neurofrontiers Neurofrontiers Making neuroscience accessible to everyone.

Frequently Asked Questions

How long is this episode of NeuroFrontiers?

This episode is 10 minutes long.

When was this NeuroFrontiers episode published?

This episode was published on June 24, 2026.

Can I download this NeuroFrontiers episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!